Prognostic significance of soluble fas and soluble fas ligand in serum of patients with complete hydatidiform moles. 2011

Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
Department of Anatomy, Dr VRK Women's Medical College & Research Centre, Hyderabad, India.

OBJECTIVE Despite of advances in diagnosis and staging, the prognosis of hydatidiform mole (HM) remains intricate. HM possesses the substantial risk of developing persistent trophoblastic disease (PTD), which is considerably high for complete hydatidiform moles (CHMs). Significance of serum soluble Fas (sFas) and soluble FasL (sFasL) has been observed in various malignancies; however, there is no report till date on HM. METHODS The serum levels of sFas and sFasL were measured using enzyme-linked immunosorbent assay in 62 patients with CHMs and 64 healthy controls. The protein concentrations were also correlated with clinicopathological parameters, β-hCG level, and clinical outcome. RESULTS The serum sFas and sFasL levels in patients with CHM were significantly higher than those in control group (mean±SD: 703.497±491.759 versus 348.141±175.24; P<0.004 and 31.17±18.758 versus 18.802± 6.775; P<0.0001, respectively). Patients who progressed to PTD demonstrated higher sFas and sFasL concentrations than those who regressed spontaneously (794.211±415.892 versus 446.69±161.382; P<0.046 and 37.55±20.337 versus 22.763±6.52; P<0.011, respectively). Furthermore, significant associations were observed among sFas, sFasL, and β-hCG levels (P<0.0001 for all associations). CONCLUSIONS Production of sFas and sFasL may play a crucial role in progression of CHM and may serve both as prognostic tool and therapeutic target in improving the clinical outcome.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006828 Hydatidiform Mole Trophoblastic hyperplasia associated with normal gestation, or molar pregnancy. It is characterized by the swelling of the CHORIONIC VILLI and elevated human CHORIONIC GONADOTROPIN. Hydatidiform moles or molar pregnancy may be categorized as complete or partial based on their gross morphology, histopathology, and karyotype. Molar Pregnancy,Pregnancy, Molar,Hydatid Mole,Hydatidiform Mole, Complete,Hydatidiform Mole, Partial,Complete Hydatidiform Mole,Complete Hydatidiform Moles,Hydatid Moles,Hydatidiform Moles,Hydatidiform Moles, Complete,Hydatidiform Moles, Partial,Molar Pregnancies,Mole, Complete Hydatidiform,Mole, Hydatid,Mole, Hydatidiform,Mole, Partial Hydatidiform,Moles, Complete Hydatidiform,Moles, Hydatid,Moles, Hydatidiform,Moles, Partial Hydatidiform,Partial Hydatidiform Mole,Partial Hydatidiform Moles,Pregnancies, Molar
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D053222 Fas Ligand Protein A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS. Antigens, CD178,CD178 Antigens,Tumor Necrosis Factor Ligand Superfamily Member 6,CD178 Antigen,CD95 Antigen Ligand,CD95 Ligand,CD95L,Fas Ligand,Fas Ligand (FasL),FasL Protein,TNF Superfamily, Member 6,Antigen, CD178
D018997 Chorionic Gonadotropin, beta Subunit, Human The beta subunit of human CHORIONIC GONADOTROPIN. Its structure is similar to the beta subunit of LUTEINIZING HORMONE, except for the additional 30 amino acids at the carboxy end with the associated carbohydrate residues. HCG-beta is used as a diagnostic marker for early detection of pregnancy, spontaneous abortion (ABORTION, SPONTANEOUS); ECTOPIC PREGNANCY; HYDATIDIFORM MOLE; CHORIOCARCINOMA; or DOWN SYNDROME. HCG-beta,Human Chorionic Gonadotropin, beta Subunit,Chorionic Gonadotropin, beta Chain, Human,Chorionic Gonadotropin, beta Polypeptide, Human,HCG, beta Subunit,HCG beta
D019014 fas Receptor A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM. Mutations in the CD95 gene are associated with cases of autoimmune lymphoproliferative syndrome. APO-1 Antigen,Antigens, CD95,CD95 Antigens,Receptors, fas,Tumor Necrosis Factor Receptor Superfamily, Member 6,fas Antigens,fas Receptors,CD95 Antigen,Fas Cell Surface Death Receptor,TNFRSF6 Receptor,fas Antigen,APO 1 Antigen,Receptor, TNFRSF6,Receptor, fas

Related Publications

Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
October 2002, Cancer biotherapy & radiopharmaceuticals,
Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
July 2001, Cancer,
Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
August 1998, The Journal of urology,
Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
February 2006, Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases,
Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
May 1989, Zhonghua fu chan ke za zhi,
Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
November 1999, European journal of obstetrics, gynecology, and reproductive biology,
Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
December 1999, Clinical and experimental immunology,
Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
July 1998, Research communications in molecular pathology and pharmacology,
Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
January 2008, Immunological investigations,
Simmi Soni, and Gayatri Rath, and Ravi Deval, and Sudha Salhan, and Ashwini Kumar Mishra, and Sunita Saxena
August 1989, Obstetrics and gynecology,
Copied contents to your clipboard!